Emylcamate

Emylcamate

Systematic (IUPAC) name
3-methyl-3-pentanol carbamate
Identifiers
CAS Number	78-28-4 Y
ATC code	N05BC03 (WHO)
PubChem	CID: 6526
ChemSpider	6278 Y
UNII	KCJ747D3R4 Y
KEGG	D07317 Y
ChEMBL	CHEMBL2104208
Chemical data
Formula	C7H15NO2
Molecular mass	145.20 g·mol−1
SMILES O=C(OC(C)(CC)CC)N
InChI InChI=1S/C7H15NO2/c1-4-7(3,5-2)10-6(8)9/h4-5H2,1-3H3,(H2,8,9) Y Key:SLWGJZPKHAXZQL-UHFFFAOYSA-N Y
(verify)

Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed.

A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared to meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:

Meprobamate	Emylcamate	Effect
175	123	ED50 (mg/kg)
600	550	LD50 (mg/kg)
3.4	4.4	Therapeutic index

Emylcamate also has a faster intra-parenteral onset then meprobabamate, 3 minutes compared to 35.

References

• Olhando para trás: um novo caminho possível para a descoberta de drogas em psicofarmacologia (Portuguese)
• The Comparative Toxicogenomics Database: Emylcamate.
• BIAM: Emylcamate (French).